A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study | Zendy

Patrick Coussement | Zendy; J P Bassand | Zendy; Carl Convens | Zendy; Mathias Vrolix | Zendy; J Boland | Zendy; Gilles Grollier | Zendy; Rolf Michels | Zendy; Alec Vahanian | Zendy; Marc Vanderheyden | Zendy; H. J. Rupprecht | Zendy; Frans Van de Werf | Zendy

Open Access

A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study

Author(s) -

Patrick Coussement,

J P Bassand,

Carl Convens,

Mathias Vrolix,

J Boland,

Gilles Grollier,

Rolf Michels,

Alec Vahanian,

Marc Vanderheyden,

H. J. Rupprecht,

Frans Van de Werf

Publication year - 2001

Publication title -

european heart journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.336

H-Index - 293

eISSN - 1522-9645

pISSN - 0195-668X

DOI - 10.1053/euhj.2001.2777

Subject(s) - medicine , timi , heparin , thrombolysis , myocardial infarction , antithrombotic , aspirin , fibrinolysis , cardiology , anesthesia , infarction

ORG31540/SR90107A, a synthetic pentasaccharide, is a selective inhibitor of factor-Xa. It was hypothesized that prolonged factor-Xa inhibition with pentasaccharide may be an effective and safe antithrombotic co-therapy in acute myocardial infarction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research